Global radiopharmaceutical company Cyclopharm (ASX:CYC) has entered into a standard commercial partnership with Yale following Technegas’ approval by the U.S. FDA | https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02766065-2A1501471
MRZ
0.275
570.7%
AR1
0.047
-70.6%
BUY
0.003
50%
MAY
0.007
-53.3%
VBC
0.15
30.4%
DTI
0.021
-30%
CR9
0.005
25%
VAR
0.005
-28.6%
LEG
0.01
25%
FRX
0.018
-28%
RKB
0.005
25%
MSG
0.008
-27.3%
TYX
0.005
25%
AYM
0.003
-25%
CPN
0.12
23.7%
NAE
0.003
-25%
SRR
0.049
22.5%
RDS
0.003
-25%
AN1
0.006
20%
T3D
0.075
-25%
MML
0.024
20%
ANG
0.215
-23.2%
GR8
0.23
17.9%
FAU
0.007
-22.2%
IMI
0.014
16.7%
SCN
0.021
-22.2%
MPR
0.007
16.7%
XPN
0.014
-22.2%
NHE
0.035
16.7%
TRI
0.022
-21.4%
BDG
0.058
16%
GLA
0.015
-21.1%
JGH
0.03
15.4%
AUR
0.023
-20.7%
AEV
0.008
14.3%
ALY
0.008
-20%
VBS
0.165
13.8%
CAV
0.004
-20%
SPQ
0.009
12.5%
FIN
0.008
-20%
